Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
NCT00325429
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:
Vildagliptin
Sponsor
Novartis